genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Incyte Corporation
Cancer
JAK Attack: Ajax Takes Aim at Myelofibrosis
Cancer
Incyte Moves to Broaden Revenue beyond Jakafi
News
Eli Lilly and Incyte – Olumiant
®
(baricitinib), with or without Gilead Sciences’ Veklury
®
(remdesivir)
Drug Discovery
Compound Library Profiling of Immunomodulators
A-Lists
10 Takeover Targets of 2018
A-Lists
Nine Takeover Targets of 2015
A-Lists
Top 25 Biotech Companies of 2015
Insights
Novel Drugs Challenge Anti-TNFs for RA Treatment
Cancer
Second Phase III Study Shows Incyte and Novartis Drug Reduces Spleen Size in Myelofibrosis
Scroll Up
Scroll Up
